Project Grant R21CA303383
Award Date
7/16/25
Completion Date
6/30/27
Dollars Obligated
$382K
Federal Agency
National Cancer Institute
Federal Grant Program
93.394
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
This Project Grant award from the National Cancer Institute under the Cancer Detection and Diagnosis Research program (CFDA 93.394) provides $997,410 to Arizona State University, in collaboration with Mayo Clinic Arizona, to develop non-invasive magnetic resonance imaging (MRI) techniques for detecting and differentiating between the invasive neuronal (NEU) and glycolytic/plurimetabolic (GPM) subtypes of high-grade glioma brain tumors. The key objectives are to: Establish and validate...
This Project Grant award of $696,133, provided by the National Cancer Institute under the Cancer Detection and Diagnosis Research program (CFDA 93.394), supports research to develop non-invasive imaging methodologies for tracking neural stem cells (NSCs) in the brains of mouse models bearing breast cancer brain metastases. The primary awardee, Northwestern University, will optimize an integrated single-photon emission microscope and magnetic resonance imaging system to enable high-resolution,...
This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $204,295 to the University of Alabama at Birmingham to conduct research aimed at integrating advanced molecular imaging of HER2 expression and vascularity to assess treatment response to radiation for HER2+ breast-to-brain metastasis. The overarching goal is to noninvasively quantify the spatial delivery of trastuzumab into brain lesions prior to radiation and systemic...
This Project Grant award of $677,998 from the National Cancer Institute's Cancer Detection and Diagnosis Research program (CFDA 93.394) will support research by The Medical College of Wisconsin, Inc. (MCW) to externally validate and integrate radio-pathomic models for delineating the true extent of glioma tumor infiltration. The research aims to develop non-invasive tools to aid in glioma treatment planning, monitoring treatment response, and guiding personalized therapies. Specifically, the...
This federal Project Grant award of $677,801, provided by the National Cancer Institute under the Cancer Detection and Diagnosis Research program (CFDA 93.394), supports research at Yale University to develop a non-invasive magnetic resonance imaging (MRI) technique called Deuterium Metabolic Imaging (DMI) for detecting and monitoring disease progression in patients with glioblastoma, an aggressive brain tumor. The key objectives are to: 1) validate the specificity of DMI for detecting active...
This Project Grant award from the National Cancer Institute (CFDA 93.394, Cancer Detection and Diagnosis Research) provides $647,398 to the Regents of the University of Michigan to develop quantitative bone marrow MRI biomarkers to assess the efficacy of novel molecularly targeted agents for myelofibrosis. The 5-year project aims to apply advanced MRI techniques, including Dixon imaging, diffusion-weighted imaging, and magnetization transfer imaging, to monitor bone marrow changes in...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $686,979 to The Regents of the University of California, San Francisco (UCSF) to develop an integrated metabolic therapy and imaging strategy for diffuse midline gliomas (DMGs), a type of malignant brain tumor in children. The key objectives are to: Investigate how the H3K27M mutation that drives DMG tumorigenesis affects tumor cell metabolism and the tumor microenvironment. Determine...
The National Cancer Institute (NCI) awarded a $1,335,041 project grant (CFDA 93.394 - Cancer Detection and Diagnosis Research) to The Regents of the University of California, San Francisco (UCSF) on August 7, 2024. The grant aims to develop metabolic therapy and imaging techniques to improve outcomes and quality of life for patients with diffuse midline gliomas (DMGs), a type of devastating brain cancer in children. Specifically, the project will determine if combined inhibition of...
This federal Project Grant award for $599,191, provided by the National Cancer Institute (CFDA 93.394 Cancer Detection and Diagnosis Research program), supports the development and validation of a 3D dynamic contrast-enhanced ultrasound (3D DCE-US) framework to characterize tumor vascular properties for liver malignancies. The goal is to introduce computational approaches that leverage the interconnected nature of voxels in 3D DCE-US imaging to capture new information beyond conventional...
This $435,827 Project Grant from the National Cancer Institute (NCI) under the CFDA 93.394 Cancer Detection and Diagnosis Research program supports research conducted by New York University (NYU) School of Medicine to develop deep learning methods for analyzing mass spectrometry imaging (MSI) data. The goal is to make MSI data more accessible to existing machine learning workflows by expanding the dimensionality of the data structure to treat each metabolite or lipid as an individual "color...